Biotech Funding News
AI-generated analysis of the latest biotech funding rounds. Real-time deal flow intelligence across the global biotech industry.
Featured Deals
NanoMed's Nanoparticles Land $320M for Solid Tumor Assault
In a sterile lab outside Boston, a clear liquid swirls with trillions of invisible particles, each engineered to slip pa...
Parabilis's PIPE: Betting on a New Class of Inflammasome Inhibitors
THESIS: Parabilis Medicines is positioned to dominate the next wave of anti-inflammatory therapeutics by targeting the N...
Corxel's $287M Bet on a New Class of Oral Degraders
The strategic significance of Corxel Pharmaceuticals' latest financing lies in its aggressive pursuit of a validated but...
Crossbow's $77M Bet on a New Class of T-Cell Engagers
Stealthy Series B fuels clinical push for conditionally active, tumor-restricted bispecifics in solid tumors.
The race to build a safer T-cell engager for solid tumors just got a new, well-funded contender. Crossbow Therapeutics, operating in stealth until now, has secured a $77M venture r...
R1 Targets Fibrosis with Novel GPCR Platform
Series A funds first-in-class oral programs against a high-mortality, treatment-starved disease area.
The $78M Series A for R1 Therapeutics signals a strategic bet on a novel approach to treating organ fibrosis, a pervasive driver of mortality with few disease-modifying therapies. ...
Prolium's Dual-Targeting Antibody Lures $50M for Solid Tumor Push
Series B funds pivotal trial for PLB-101, a bispecific designed to outmaneuver TIGIT/PVRIG resistance.
THESIS — Prolium Bioscience is positioned to capture value in the crowded immuno-oncology space by advancing a rationally designed bispecific antibody that co-targets TIGIT and PVR...
QL Biopharm's 'Molecular Glue' Approach Lures $73M
Series C fuels a push to drug the 'undruggable' proteome, a hot frontier in oncology and beyond.
In a lab outside Boston, scientists at QL Biopharm are designing molecules not to fit into a protein's active site, but to stick two proteins together that nature never intended to...
Atrium's $270M Bet on a New Class of Inflammasome Inhibitors
Series B funds a pivotal test for lead oral drug ATI-2301 in ulcerative colitis.
Atrium Therapeutics has secured a $270 million Series B round to advance its pipeline of oral, small-molecule inflammasome inhibitors, with lead candidate ATI-2301 now headed for a...
BreezeBio's $60M Bet on a New Class of Neuroinflammation Modulators
Series B funds lead program BZ-101, a brain-penetrant NLRP3 inhibitor, into Phase 2 for Parkinson's disease.
The neuroinflammation space is heating up, and BreezeBio's latest financing positions it as a serious contender with a differentiated, brain-penetrant approach. The company's $60 m...
Slate's $130M Bet on Epigenetic Control of Inflammation
Series B fuels clinical push for novel KDM5 inhibitors in autoimmune disease, challenging JAK dominance.
The strategic significance of Slate Medicines' latest financing lies in a high-stakes wager on precision epigenetics as a next-generation modality for immune dysregulation. Moving ...
Altesa's $75M Bet: Upending COPD by Preventing Exacerbations
Series B fuels pivotal trial for Vapendavir, a novel antiviral targeting the root cause of acute respiratory crises.
THESIS: Altesa BioSciences is positioned to create a new, prophylactic standard of care in COPD by directly preventing the viral infections that drive devastating and costly acute ...
Korsana's $175M Bet on a New Class of Obesity Drugs
The biotech is advancing oral GLP-1/GIP receptor modulators, aiming to outmaneuver injectable giants.
In a lab outside Boston, chemists are meticulously tweaking molecular structures, not for another injectable blockbuster, but for a pill designed to mimic the intricate hormonal da...
ILiAD's $115M Bet on a Next-Gen Pertussis Vaccine
Private funding fuels Phase 3 trial for BPZE1, aiming to block transmission of whooping cough.
ILiAD Biotechnologies has secured $115 million in venture financing to advance its live attenuated pertussis vaccine candidate, BPZE1, into a pivotal Phase 3 trial. The Florida-bas...
QuantX's $85M Bet on a New Class of Neurodegenerative Drugs
Series B funds clinical push for novel tau aggregation inhibitor QXB-101, targeting Alzheimer's and beyond.
The race to treat neurodegenerative diseases is shifting beyond amyloid, and QuantX Biosciences is placing a major bet on directly targeting pathological tau. The company's $85M Se...
Angitia's $130M Bet on a New Bone Biology Paradigm
Series D fuels late-stage push for first-in-class sclerostin/activin A bispecific in high-stakes musculoskeletal race.
The musculoskeletal therapeutic arena, long dominated by small molecules and single-target biologics, is being reshaped by a new wave of sophisticated antibody engineering. Angitia...
Third Arc Bio's $52M Bet on a New Class of Targeted Degraders
Series A fuels clinical push for a novel protein degrader platform with a lead program in oncology.
THESIS — Third Arc Bio is positioned to deliver outsized returns by advancing a novel class of molecular glues that selectively degrade disease-causing proteins previously consider...
Breakthru Medicine's PIPE Funds Mid-Stage Neurodegenerative Push
A $60M private placement will advance two clinical-stage programs targeting protein misfolding.
Breakthru Medicine has secured $60 million in a private investment in public equity (PIPE) financing to advance its pipeline of small molecules designed to correct protein misfoldi...
Tenpoint's $85M Bet on Retinal Regeneration
A stealthy biotech emerges with an ambitious plan to restore vision by reprogramming eye cells.
In a darkened lab, a cluster of human retinal cells, coaxed from a different fate, begins to respond to light. This is the quiet, foundational experiment at Tenpoint Therapeutics, ...
TRexBio's $50M PIPE Fuels Tissue-Resident T-Cell Ambitions
Private funding bets on novel immunology platform targeting IBD and fibrosis, sidestepping public market volatility.
The real story behind TRexBio's quiet $50M PIPE is a high-conviction bet on a novel immunology axis that has largely eluded drug developers: tissue-resident T-cells (TRTs). While m...
Corxel's $287M Bet on a New Class of Oral Degraders
Series D fuels pivotal trial for CORX-101, targeting a high-value oncology niche with a differentiated mechanism.
The strategic significance of Corxel Pharmaceuticals' latest financing lies in its aggressive pursuit of a validated but crowded target: KRAS G12C. The company is betting that its ...
Mendra's $82M Bet: Reprogramming the Brain's Immune System
Series A fuels clinical push for a novel glial-targeting approach to neurodegenerative disease.
THESIS: Mendra is positioned to deliver outsized returns by pioneering a first-in-class therapeutic strategy that reprograms the brain's resident immune cells to halt and potential...
Think Bioscience's AI Engine Aims to Crack the Small Molecule Code
A $55M Series B fuels its quest to design drugs for 'undruggable' targets, moving beyond simple binding.
In a Boulder, Colorado lab, scientists aren't just screening for molecules that bind to a disease target; they are instructing an AI to design compounds that perform specific, disr...
Exciva's $59M Bet on a Novel Immuno-Oncology Mechanism
Series B funds first-in-human trials for a dual-acting myeloid cell engager.
Exciva has secured a $59 million venture round to advance its pipeline of engineered protein therapies designed to reprogram the tumor microenvironment. The biotech is developing E...
Cytotheryx's $60M Bet on a New Class of Senolytics
Funding aims to push first-in-class cellular reprogramming therapy for fibrosis into the clinic, challenging a crowded field.
The race to develop clinically effective senolytics—drugs that clear aged, dysfunctional 'senescent' cells—has a new, well-funded contender. Cytotheryx has secured $60M in venture ...
Proxima's $80M PIPE Fuels a Precision Strike in the Radiopharmaceutical Arena
Private capital backs a stealthy contender in the red-hot targeted radiotherapy space, signaling a crowded but high-stakes race.
The $80M private investment in public equity (PIPE) secured by Proxima underscores a high-conviction bet on the next wave of precision radiopharmaceuticals, a sector defined by its...
Vibrant's PIPE Fuels a New Wave in Tumor Microenvironment Targeting
A $61M bet on the clinical validation of its dual-targeting cytokine platform for solid tumors.
THESIS — Vibrant Therapeutics is positioned to redefine the treatment of immunologically 'cold' solid tumors by pharmacologically reprogramming the tumor microenvironment, a high-v...
Cytotheryx's $60M Bet on a New Era of Cell Therapy
A debt financing fuels the push to make complex cell therapies more accessible and manufacturable.
In a sterile clean room, a bioreactor hums, nurturing a living medicine—a patient's own immune cells, genetically reprogrammed to hunt cancer. For Cytotheryx, this precise, scalabl...
Kinaset's $103M Bet on a New Inhaled JAK Inhibitor
Series B funds pivotal trial for KN-002 in severe asthma, challenging oral rivals.
Kinaset Therapeutics secured $103 million in a venture round to advance its lead inhaled JAK inhibitor, KN-002, into a pivotal Phase 2b trial for severe, uncontrolled asthma. The c...
AirNexis's $200M Bet on a New Class of Inhaled RNA Therapies
Series B fuels pivotal trial for ANX-101, a first-in-class inhaled siRNA for severe asthma, challenging biologic incumbents.
The race to displace injectable biologics in severe asthma with a more convenient, durable inhaled therapy just got a major new contender. AirNexis Therapeutics has secured a $200 ...
Medipost IPO Bets Big on Next-Gen Cell Therapy Platform
A $140M public debut aims to advance off-the-shelf, engineered cell therapies beyond autologous CAR-T limitations.
The strategic significance of Medipost's public offering lies in a high-stakes wager on allogeneic, or 'off-the-shelf,' cell therapies. This move targets the core scalability and a...
Syncona Doubles Down on Beacon's Gene Therapy for Inherited Blindness
A $75M venture round fuels the lead program AGTC-501 into a pivotal trial, targeting a $1B+ market with a one-time treatment.
The latest financing for Beacon Therapeutics underscores a high-conviction bet on gene therapy's potential to permanently restore vision in patients with inherited retinal diseases...
Alveus Bets $160M on a New Class of Inhaled Drugs
The biotech is advancing a pipeline of targeted protein degraders designed to be delivered directly to the lungs.
In a lab outside Boston, scientists are engineering molecules to do something unprecedented: slip deep into lung tissue, latch onto disease-causing proteins, and mark them for cell...
EpiBiologics' $107M Bet on Next-Gen Protein Degradation
Stealthy funding round aims to move targeted degradation beyond oncology into immunology and neurology.
The quiet but substantial $107M venture round for EpiBiologics signals a strategic push to expand the therapeutic reach of targeted protein degradation. While the field has been do...
Parabilis's PIPE: Betting on a New Class of Inflammasome Inhibitors
A $305M private placement backs a precision approach to sterile inflammation, moving beyond IL-1.
THESIS: Parabilis Medicines is positioned to dominate the next wave of anti-inflammatory therapeutics by targeting the NLRP3 inflammasome with a pipeline of oral, small-molecule in...
Diagonal's $125M PIPE Bets on Agonist Antibody Platform
Private financing to advance lead bispecific antibody DGN-001 into Phase 2 for a rare vascular disease.
Diagonal Therapeutics has secured $125 million in a private investment in public equity (PIPE) financing to propel its lead bispecific antibody agonist, DGN-001, into mid-stage tes...
Poplar's $50M Series A Bets on a New Class of Oral RNA Modulators
Stealthy biotech emerges with platform targeting RNA-protein interactions for neurological and metabolic disorders.
The quiet emergence of Poplar Therapeutics with a $50 million Series A signals a sophisticated bet on a novel therapeutic axis: drugging RNA-protein interactions with oral small mo...
Soley's PIPE Bets on a New Class of Epigenetic Degraders
A $200M private placement fuels the clinical push for a first-in-class dual-targeted degrader in oncology.
THESIS: Soley Therapeutics is positioned to define a new therapeutic class with its lead dual-targeted epigenetic degrader, SOL-101, making its recent capital raise a calculated be...
Corsera Health's $80M Bet on a Dual-Mechanism Cancer Drug
Series B funds a pivotal Phase 2 trial for lead bispecific antibody COR-101.
Corsera Health secured an $80 million Series B to advance a novel bispecific antibody designed to simultaneously target two immune checkpoints in solid tumors. The Boston-based bio...
Rakuten Medical's Illuminating Bet on Precision Cancer Killers
A $100M venture round fuels the clinical push for its light-activated antibody platform, betting on a targeted oncology niche.
In a darkened treatment room, a patient receives an infusion of a seemingly inert antibody, one engineered to seek out tumors. Hours later, a specific wavelength of red light is ap...
Syremis Targets Fibrosis with a New Class of Oral Kinase Inhibitors
A $165M Series A funds a dual-mechanism attack on IPF and systemic sclerosis, moving into Phase 2.
THESIS: Syremis Therapeutics is positioned to redefine the treatment landscape for fibrotic diseases by advancing a novel, oral small-molecule platform that simultaneously targets ...
Syneron Bio's $100M Bet on a New Class of RNA Degraders
Series A fuels push into targeted RNA degradation, a nascent but high-potential modality challenging PROTAC dominance.
The $100M Series A for Syneron Bio represents a strategic wager on targeted RNA degradation, an emerging modality aiming to drug the 'undruggable' transcriptome beyond the reach of...
Atavistik Bio's $120M Bet on 'Undruggable' Proteins
A new wave of biotechs is using AI to map the cell's hidden chemical interactions, unlocking novel drug targets.
In a lab outside Boston, scientists are not just looking at proteins; they are listening to the whispers of the cell. At Atavistik Bio, the mission is to decode the ancient, hidden...
Addition Therapeutics lands $100M grant for novel RNA platform
Non-dilutive funding will advance a pipeline of programmable RNA medicines, including a lead candidate for solid tumors.
A $100 million grant will propel Addition Therapeutics and its platform for designing programmable, circular RNA therapeutics into the clinic. The stealth-mode biotech is developin...
Ambros Targets Rare Pain Syndrome with $125M Series A
Clinical-stage biotech advances novel small molecule for intractable CRPS-1, a high-value rare disease niche.
The $125 million Series A financing for Ambros Therapeutics represents a strategic bet on a high-need, high-value niche within neuroscience and rare diseases: complex regional pain...
Aeovian's $55M Series B Bets on mTORC1 Inhibition Beyond Rapalogs
Funding advances AVN-001, a selective mTORC1 inhibitor for TSC and aging-related diseases, challenging first-gen limitations.
The mTORC1 pathway, a central regulator of cell growth and metabolism, has long been a validated but problematic target. While rapalogs like sirolimus are approved for tuberous scl...
Link Cell Therapies Aims to Unlock Off-the-Shelf CAR-T
A $60M seed round fuels a new approach to manufacturing cell therapies, targeting cost and scale.
In a sterile lab, a bioreactor hums, not with patient-derived immune cells, but with a master cell line engineered to become a universal starting point for cancer-fighting CAR-Ts. ...
Chai Discovery's $130M Bet on a New Class of Neurodegenerative Drugs
Series A funds clinical push for first-in-class small molecules targeting TDP-43 aggregation in ALS and FTD.
THESIS: Chai Discovery is positioned to define a new therapeutic class for neurodegenerative diseases by targeting the pathological aggregation of TDP-43, a root cause of ALS and f...
Prolynx's $70M Series A Backs a New Protein Degrader Play
The biotech will advance its lead candidate, PLX-101, into Phase 2 trials for solid tumors.
Prolynx has secured $70 million in a Series A round to propel its targeted protein degrader platform and clinical pipeline. The San Francisco-based biotech is developing a new clas...
BlossomHill's $84M Bet on a Novel NLRP3 Inhibitor Platform
Series B funds a new wave of inflammasome-targeting therapies for autoimmune and fibrotic diseases.
The strategic significance of BlossomHill Therapeutics' $84M Series B lies in a high-stakes wager on NLRP3 inflammasome inhibition, a platform with broad applicability across infla...
D3 Bio's $108M Bet on a New Class of RAS Inhibitors
Venture round fuels clinical push for D3-001, targeting the 'undruggable' KRAS G12D in solid tumors.
The race to drug the full spectrum of oncogenic RAS mutations intensifies with D3 Bio's quiet but substantial $108M venture financing. While the investor syndicate remains undisclo...
SanegeneBio's RNAi Platform Targets a $5B Neurodegenerative Blind Spot
Series B fuels pivotal trial for SGB-101, a novel RNAi therapeutic for C9orf72 ALS/FTD, as competitors falter.
THESIS: SanegeneBio is positioned to capture a multi-billion dollar neurodegenerative disease market with a clinically de-risked, intrathecally delivered RNA interference (RNAi) pl...
OTR's 'Molecular Glue' Aims to Revive Failed Cancer Drugs
A $100M venture round fuels a high-risk bet on rescuing shelved oncology assets through targeted protein degradation.
In a lab outside Boston, scientists at OTR Therapeutics are sifting through the pharmaceutical industry's graveyard. Their target isn't a new protein, but a collection of once-prom...
SciNeuro's $53M PIPE Fuels Parkinson's Pipeline
Private funding backs mid-stage trial for a novel LRRK2 inhibitor, targeting a high-value neuroscience mechanism.
SciNeuro Pharmaceuticals has secured a $53 million private investment to advance its lead candidate, a brain-penetrant LRRK2 inhibitor for Parkinson's disease, into a Phase 2 trial...
Triana's $120M Bet on a New Class of Protein Degraders
Series B fuels clinical push for a potentially best-in-class KRAS degrader, challenging Amgen's sotorasib.
The race to drug the 'undruggable' KRAS oncogene is entering its next, more elegant phase: degradation. Triana Biomedicines' $120M Series B, closed this week, is a direct wager tha...
Protego's $130M Bet on a New Class of Protein Degraders
Series B fuels clinical push for PROTACs targeting 'undruggable' oncology and immunology pathways.
The strategic significance of Protego Biopharma's $130M Series B lies in the high-stakes race to validate next-generation protein degraders. The company is advancing a platform of ...
Aspen's Autologous Neurons March Toward the Clinic
A $115M venture round fuels the push to transplant a patient's own cells to fight Parkinson's.
In a clean room in San Diego, a patient's own skin cell is on a journey to become a dopamine neuron, destined for a one-way trip back into their brain. This is the core promise of ...
TheraDiag's $210M Bet on a New Class of Targeted Degraders
Public offering fuels pivotal trial for novel PROTAC targeting a notorious cancer protein.
THESIS — TheraDiag is positioned to deliver outsized returns by advancing a first-in-class protein degrader into registrational studies for genetically defined solid tumors. THE SC...
Profluent's $106M Bet on AI-Designed Proteins
Spark Capital leads a major round to advance generative biology into the clinic.
Profluent, a pioneer in generative AI for protein design, has secured a $106 million venture round to propel its computationally engineered therapies toward human testing. The comp...
Artios Doubles Down on DNA Damage Response in Oncology
$115M Series D fuels late-stage push for ATR inhibitor ART6040, targeting a crowded but high-stakes niche.
The latest financing for Artios Pharma underscores a continued strategic bet on synthetic lethality and the DNA Damage Response (DDR) pathway as a cornerstone of next-generation on...
Solve Therapeutics Bets $120M on a New Class of Oral Degraders
Series B funds first-in-class oral degrader for autoimmune disease, challenging injectable biologics.
The autoimmune space, dominated by injectable antibodies, is ripe for disruption by oral therapies with novel mechanisms. Solve Therapeutics is placing a major bet on that thesis, ...
Gate Bioscience: Targeting the 'Undruggable' Escape
A $65M bet on a novel extracellular drug class to intercept disease-causing proteins before they enter cells.
THESIS — Gate Bioscience is pioneering a first-in-class therapeutic modality that intercepts pathogenic proteins in the extracellular space, offering a definitive solution for dise...
NanoMed's Nanoparticles Land $320M for Solid Tumor Assault
Series C fuels a new wave of targeted, non-viral gene therapies aimed at notoriously hard-to-treat cancers.
In a sterile lab outside Boston, a clear liquid swirls with trillions of invisible particles, each engineered to slip past the body's defenses and deliver a genetic payload directl...
MediVax AI's $45M Series C Fuels AI-Designed Vaccine Pipeline
Khosla Ventures backs computational platform advancing two novel immunogens into the clinic.
MediVax AI has secured $45 million in a Series C round led by Khosla Ventures to advance its computationally designed vaccine candidates into human trials. The biotech leverages a ...